CALIFORNIA RESOURCES CORP
CRCNYSETrading Snapshot
- Day Range
- $50.31 – $51.76
- 52-Week Range
- $43.25 – $71.98
- Volume
- $2.43B
- Avg Volume
- $2.99B
- Shares Outstanding
- 88.8M
- Next Earnings
- Nov 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.60B
- Last Q Revenue
- $1.30B
- P/E Ratio
- -39.5
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-1.36
- Dividend Yield
- 3.09%
- Dilution (1yr)
- −5.2%
Why Investors Own CRC
- ✓High-growth profile — revenue up -3.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CALIFORNIA RESOURCES CORP
CRC
StockOtter · stockotter.spaceAbout CALIFORNIA RESOURCES CORP
California Resources Corporation operates as an independent energy and carbon management company in the United States. The company operates in two segments, Oil and Natural Gas, and Carbon Management. It explores, develops, and produces crude oil, oil condensate, natural gas liquids and natural gas to california refineries, marketers, and other purchasers. The company also provides Carbon TerraVault which builds, installs, operates, and maintains CO2 capture equipment, transportation assets, and storage facilities. In addition, it owns and operates power generation facilities, as well as smaller gas-fired power plants used to generate power for oil and natural gas operations. The company was incorporated in 2014 and is based in Long Beach, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Head to Head Comparison: California Resources (NYSE:CRC) versus Kinetik (NYSE:KNTK)
California Resources (NYSE: CRC - Get Free Report) and Kinetik (NYSE: KNTK - Get Free Report) are both mid-cap energy companies, but which is the superior investment? We will compare the two companies based on the streng
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, bl
California Resources to Divest Uinta Basin Assets for $90 Million
CRC plans to sell its non-core Uinta Basin assets for about $90 million, freeing cash to support its California-focused strategy and capital allocation.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
California Resources Corporation Announces Divestiture of Uinta Basin Assets
LONG BEACH, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) today announced the signing of an agreement to divest its Uinta Basin assets to an undisclosed buyer for total cash cons
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from